February 6, 2013
Vancouver, BC – One of Canada’s most successful research commercialization programs has awarded additional funding to the Vancouver Prostate Centre’s Translational Research Initiative for Accelerated Discovery and Development program (PC-TRiADD). PC-TRiADD is one of two Centres of Excellence for Commercialization and Research (CECR) in BC to be awarded this funding and will be receiving $11.33 million over five years.
The funding is in addition to the $15 million CECR gave PC-TRiADD in 2008. The money will help attract the best researchers/clinicians, support discovery and development of new drugs and biomarker tests as well as the commercialization of spin-off companies, such as OncoGenex and Aquinox.
Dr. Martin Gleave (Right)
“This new funding from the CECR program will help accelerate research and commercialization programs in BC,” says Dr. Martin Gleave, Executive Director of the Vancouver Prostate Centre, CEO of PC-TRiADD, researcher with VCH Research Institute and Distinguished Professor at the University of British Columbia. “It will help commercialize our best anti-cancer drug candidates and create new economic opportunities for the benefit of Canada.”
Although focused on prostate cancer, many of PC-TRiADD's services and discoveries are applicable to other cancers, such as breast, lung, colon, and bladder, and other industries including forestry and fisheries. CECR funding will help the Prostate Centre continue to strengthen the relationships between academic research and corporate biotech.
About Vancouver Prostate Centre and PC-TRiADD
PC-TRiADD is a translational research centre focused on improving outcomes in prostate cancer. The Vancouver Prostate Centre focuses on the discovery of molecular mechanisms of cancer progression, therapeutic resistance, and the development of new treatments, services, and products to improve cancer patient care. The VPC is a UBC & VGH and National Centre of Excellence with a multi-disciplinary team of 20 senior basic science and clinical researchers and more than 130 staff. The VPC has a proven track record of success in research commercialization, integrating the expertise of scientists and clinicians in urology, cellular and molecular biology, pharmacology, socio-behavioural sciences, genomics, and medical oncology. For more information, visit www.prostatecentre.com and www.pctriadd.com.
About Vancouver Coastal Health Research Institute (VCHRI)
Vancouver Coastal Health Research Institute is a world leader in translational health research. It is the research body of the Vancouver Coastal Health Authority and includes BC’s largest academic and teaching health sciences centres: Vancouver General Hospital, UBC Hospital, and GF Strong Rehabilitation Centre. VCHRI is academically affiliated with UBC Faculty of Medicine and is one of Canada’s top funded research centres receiving $80-100 million annually. For more information, visit www.vchri.ca.
About the Centres of Excellence for Commercialization and Research (CECR)
The CECR program bridges the gap between innovation and commercialization to share the knowledge and resources that bring innovations to market faster. CECR funding recipients adopt different models to best serve the needs of industry partners by acting as investors, incubators, and service providers. The CECR program was created in 2007 with a $285 million investment over five years and supports 22 active centres across the country.
Dr. Graeme Boniface, PhD
Chief Operating Officer, Vancouver Prostate Centre
Director, Stakeholder Relations and Public Affairs
Tel: 604.875.4111 ext. 66687